InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,461.36
(
-0.22%
)
US TECH 100
19,193.60
(
-0.34%
)
Dow Jones
39,200.32
(
0.17%
)
Brent Oil
85.39
(
0.45%
)
Bitcoin
64,096.57
(
-1.12%
)
Post# of 252283
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: ariadndndough post# 177930

Thursday, 05/15/2014 6:10:39 PM

Thursday, May 15, 2014 6:10:39 PM

Post# of 252283
I would be careful here with TGR-1202....the list of PI3K inhibitors with impressive activity at early stage only to disappoint in Phase 2, continues to grow. I know its early and 6 CLL patients is too few to judge, but 67% nodal response (down from 75% at ASH) does not compare favorably with single-agent idelalisib's 81%, not to mention ibrutinib's 100%.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up